The Add-Aspirin trial is for people who have had, or have started treatment for, cancer of the breast, stomach, oesophagus (food pipe), prostate or bowel.
We are aiming to find out whether taking aspirin daily for 5 years after treatment for an early stage cancer (cancer that has not spread widely), stops or delays the cancer coming back. This study will compare groups of people who take aspirin and those who take placebo tablets.
There have already been some studies testing the beneficial effect of aspirin on heart disease. In these studies aspirin appeared to reduce the number of people who developed cancer and, if people did develop cancer, it appeared to be less likely to spread. Researchers therefore believe that aspirin may stop cancer coming back in people who have had treatment for an early stage cancer. But, importantly, since previous studies were not specifically designed to answer this question, there is not any reliable evidence yet.
Individuals can take part in the Add-Aspirin study if they have had (or are currently having) treatment for an early stage cancer of the breast, bowel, stomach, oesophagus or prostate. Individuals who have taken part in other trials and satisfy the eligibility criteria might also be eligible.